Lipoplexes (LPs) are well-established nucleic acid carriers that utilize cationic lipids to form stable complexes with mRNA through electrostatic interactions. Since their first demonstration in the 1980s, LPs have become a versatile delivery platform, particularly valuable for in vitro and ex vivo applications due to their tunable surface charge, high transfection efficiency, and excellent mRNA protection capability.
Fig. 1 Lipid Nanoparticles (LNPs) Architecture.1
Why LNPs Excel:
At Creative Biolabs, we pioneer for next-generation LNP solutions for:
Lipid Nanoparticles (LNPs) represent the most advanced non-viral mRNA delivery system, offering unparalleled formulation flexibility and preclinical translation potential. Through precise optimization of ionizable lipids, phospholipids, cholesterol, and PEG-lipids, LNPs achieve superior mRNA protection, targeted delivery, and batch-to-batch consistency. Below we detail the key application areas where LNP technology delivers breakthrough performance.
| Application Area | Technical Advantages | Performance Metrics |
|---|---|---|
| Vaccine Development |
|
|
| Gene Editing |
|
|
| Rare Disease Therapy |
|
|
| Cancer Immunotherapy |
|
|
| Research |
|
|
Every therapeutic application demands unique delivery characteristics - whether it's tissue-specific targeting, sustained protein expression, or enhanced cellular uptake. Our LNP platform offers unparalleled formulation flexibility through systematic optimization of four key lipid components. We work closely with you to design delivery systems that align perfectly with your biological objectives and development timeline.
While LP systems excel in research settings, our LNP platform has demonstrated success in preclinical research applications. The same technology that powered revolutionary mRNA vaccines can be adapted for your gene therapy, protein replacement, or vaccine development needs. From small-scale research batches to preclinical-scale production, we maintain consistent quality and performance.
Successful mRNA delivery requires more than just nanoparticles - it demands integrated expertise in formulation science, biology, and therapeutic development. Our team provides end-to-end support from initial design through in vivo validation, serving as an extension of your research team to overcome delivery challenges and accelerate progress.
Creative Biolabs delivers end-to-end lipid nanoparticle (LNP) development services, providing tailored solutions from initial design to production. Our structured workflow ensures optimal mRNA delivery with rigorous quality control at every stage—balancing speed, flexibility, and precision to meet your therapeutic, vaccine, or gene editing goals.
Fig.2 Systematic Development Workflow for LNP Platform.
Explore Our LNP Solutions
Lipoplex vs. Lipid Nanoparticles (LNPs)
| Feature | Lipoplex | Lipid Nanoparticles (LNPs) |
|---|---|---|
| Core Composition | Electrostatic complexes of cationic lipids + nucleic acids (mRNA/DNA) | Encapsulated nucleic acids (e.g., mRNA) in a lipid shell |
| Lipid Composition | Dominated by cationic lipids (e.g., DOTAP, DOTMA) | Ionizable lipids (e.g., DLin-MC3-DMA) + helper lipids (DSPC, cholesterol, PEG-lipids) |
| Formation Mechanism | Charge-driven self-assembly (lipid + nucleic acid mixing) | Spontaneous nanoprecipitation (microfluidic mixing) |
| Structure | Heterogeneous, multilayered aggregates | Uniform, core-shell nanoparticles with lipid bilayer |
| Size | Larger (200–1000 nm), polydisperse | Smaller (50–100 nm), monodisperse |
| Surface Charge | Positive (due to cationic lipids) | Neutral/slightly negative (PEG-shielded) |
| Nucleic Acid Protection | Moderate (exposed to surface) | High (fully encapsulated) |
| Transfection Efficiency | High in vitro, but cytotoxic | High in vitro/vivo, improved biocompatibility |
| Stability | Low (aggregation-prone) | High (PEG-stabilized, long circulation) |
| Primary Applications | Early-stage gene therapy research | Clinical applications (e.g., mRNA vaccines, siRNA therapeutics) |
A: Ionizable lipids, phospholipids, cholesterol, and PEG lipids—each component is precisely optimized for your application.
A: By dynamic light scattering (DLS) and three-angle detection (Malvern Panalytical).
A: Yes, we have successfully achieved co-delivery of mRNA/sgRNA with editing efficiencies exceeding 60% (T7E1 assay).
A: LNP uses a four-component system with better tissue targeting and in vivo stability; LP is more suitable for in vitro transfection and has a simpler formulation.
A: The standard formulation is stable for 7 days at 4°C and can be stored for a long time at -20°C.
Creative Biolabs leverages advanced lipid nanoparticle (LNP) technology and deep expertise in nucleic acid delivery to create bespoke non-viral delivery systems. Our platform engineers high-performance LNP formulations through precise optimization of ionizable lipid selection, lipid ratios, PEGylation, and encapsulation parameters, enabling robust delivery efficiency and protein expression across therapeutic applications. With comprehensive capabilities spanning from proprietary lipid library screening to preclinical-scale manufacturing, we deliver end-to-end LNP development supported by stringent analytical characterization and rigorous quality-controlled processes. Whether you're developing mRNA vaccines, gene therapies, or CRISPR-based treatments, our LNP solutions provide the ideal combination of payload protection, tissue targeting, and preclinical development readiness. Contact us to power your nucleic acid research with customized LNP formulations engineered to your specific biological targets and development goals.
Reference
